3611 Valley Centre Drive
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.
In April 2016, ACADIA received FDA approval for NUPLAZID® (pimavanserin), the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. In addition, ACADIA has ongoing clinical development efforts in additional areas with significant unmet need, including pimavanserin for dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and major depressive disorder and trofinetide for Rett syndrome.
Further information about ACADIA can be found at: www.acadia-pharm.com.
Stock Symbol: ACAD
Stock Exchange: NASDAQ
394 articles with ACADIA Pharmaceuticals
ACADIA to Host Conference Call and Webcast on Wednesday, October 30, 2019, at 4:30 p.m. Eastern Time
ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress
Pimavanserin as adjunctive treatment to SSRI/SNRI therapies significantly improved sexual dysfunction symptoms compared to placebo in MDD patients
ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Meeting
ACADIA Pharmaceuticals Inc. announced that the presentation of the results from the Phase 3 HARMONY study of pimavanserin in dementia-related psychosis has been accepted for a late-breaking oral communication at the upcoming 12th Clinical Trials on Alzheimer’s Disease Meeting, December 4-7, 2019 in San Diego, California.
ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019
ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), announced today that positive results from the Phase 2 CLARITY study evaluating pimavanserin as adjunctive treatment in patients with major depressive disorder (MDD) have been published online by The Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology (ASCP)
ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinson’s Disease and Movement Disorders
Pimavanserin as monotherapy or adjunct to SSRI/SNRI therapies significantly improved depression symptoms for Parkinson’s patients
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Sept. 20, 2019
ACADIA Pharmaceuticals Inc. announced the closing of its previously announced underwritten public offering of 7,187,500 shares of its common stock, which includes 937,500 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $40.00 per share.
ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings
New data presented at the International Congress of Parkinson’s Disease and Movement Disorders will highlight treatment benefit of pimavanserin in patients with comorbid Parkinson’s disease and depression
ACADIA Pharmaceuticals Inc. announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock, offered at a price to the public of $40.00 per share.
ACADIA Pharmaceuticals Inc. announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $250,000,000 of its common stock.
9/16/2019Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis
ACADIA Pharmaceuticals Inc. announced that its Phase 3 HARMONY study, a double-blind, placebo-controlled relapse prevention trial evaluating pimavanserin for the treatment of dementia-related psychosis, met its primary endpoint, demonstrating a highly statistically significant longer time to relapse of psychosis with pimavanserin compared to placebo in a planned interim efficacy analysis.
Shares of ACADIA Pharmaceuticals are up nearly 70% after the company announced it halted a Phase III psychosis trial early after its Parkinson’s disease drug Nuplazid hit primary endpoints and positioned the company to seek another potential regulatory approval.
ACADIA Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 11, 2019
Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, September 11, 2019 at 8:45 a.m. Eastern Time in New York City.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, announced its financial results for the second quarter ended June 30, 2019.
In the trial, 396 patients with moderate-to-severe psychotic symptoms related to adult schizophrenia received either Nuplazid or placebo added to their current antipsychotic treatment. The patients receiving Nuplazid showed a consistent trend in symptom improvement but did not hit statistical sig...
ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced top-line results from its Phase 3 ENHANCE study, which evaluated pimavanserin as an adjunctive treatment in adult schizophrenia patients with persistent inadequate response to their current antipsychotic therapy.
ACADIA to Host Conference Call and Webcast on Wednesday, July 31, 2019, at 4:30 p.m. Eastern Time
New National Event Series "Parkinson's IQ + You" Launches to Educate and Empower Parkinson's Disease Patients and Care Partners
"Parkinson's IQ + You" events are designed to empower people with Parkinson's and care partners to manage the disease, learn about research participation and connect with local resources